Sweetch is the developer of hyper-personalized engagement solutions for chronic conditions.
Sweetch is the first behavioral science company to leverage AI and EI (emotional intelligence) enabling pharmaceutical companies, device manufacturers, payers, and healthcare providers to build continuous relationships and engage with every individual patient with chronic conditions, at scale.
The company provides a clinically validated digital therapeutics platform that moves individuals to achieve their health goals with hyper-personalized recommendations in the right time, tone and real-world context every step of the way throughout their health journey.
Analyzing every user’s personality, behavior and context, Sweetch’s proprietary algorithms identify the individual’s compliance patterns and continuously adapt recommendations to each user, leading to significantly improved adherence to treatment programs, better health outcomes and improved healthcare economics. Sweetch is HIPAA and GDPR compliant.
Noaber is one of the investors in Sweetch.